Background. Patients with acute coronary syndrome (ACS) and oncological diseases (OD) have the increased risk of development of acute kidney injury (AKI) that can worsen the prognosis of a disease. KIM-1 (kidney injury molecule) is a perspective biomarker for early diagnostics of AKI.
Objective. Evaluation of diagnostic and predictive value of urinary KIM-1 levels in patients with ACS and OD.
Material and methods. The study included 87 patients. Patients were divided in two groups: 1) main group: ACS in combination with OD (ACS+OD; n=40); 2) comparison group: ACS without OD (ACS-OD; n=47). On the first day of admission to the hospital, average portion of morning urine was collected in order to determine the KIM-1 level (pg/ml).
Results. The median urinary KIM-1 level in ACS patients (n=87) was 725.6 (420.0-1087.5) pg/ml. Patients in the ACS+OD group had higher KIM-1 levels 921.0 (425.1-1314.8) and 658.0 (345.6-921.4) pg/ml (Р=0.011). In patients with AKI (n=28) compared to the patients without AKI (n=59), urinary KIM-1 level was higher: 999.3 (478.7-1303.3) and 668.2 (365.5-955.6) pg/ml
(Р =0.023). ROC analysis revealed that urinary KIM-1 level > 1047.23 pg/ml allowed to predict the development of contrast-induced AKI (CI-AKI) in ACS patients after selective coronary angiography (n=79) (AUC – 0.774; 95% CI, 0.666-0.860; Р <0.001); and also in patients with ACS and OD (n=35) (AUC – 0.728; 95% CI, 0.552-0.864; Р=0.010) with a cut-off point > 1221.49 pg/ml.
Conclusion. The increased urinary KIM-1 level was observed in development of AKI; however, KIM-1 showed the greatest importance as an early biomarker of CI-AKI.

Keywords: acute kidney injury, contrast-induced acute kidney injury, KIM-1, acute coronary syndrome, oncological diseases